Background
Methods
Study patients and data collection
Adiposity measurement
Statistical analyses
Results
Patient characteristics
Parameters | Cohort | VAT% < 31.89 % | VAT% ≥ 31.89 % |
P value |
---|---|---|---|---|
N = 200 |
N = 100 |
N = 100 | ||
Median age (range), years | 54 (28–84) | 52 (28–82) | 57 (34–84) |
<0.001
a
|
Premenopausal patients (%) | 83 (41.5 %) | 52 (52.0 %) | 31 (31.0 %) |
0.003
b
|
Hypertension (%) | 57 (28.5 %) | 19 (19.0 %) | 38 (38.0 %) |
0.003
b
|
Diabetes (%) | 27 (13.5 %) | 9 (9.0 %) | 18 (18.0 %) | 0.063b
|
Positive peritoneal cytology (%) | 16 (9.4 %) n = 171 | 10 (11.6 %) n = 86 | 6 (7.1 %) n = 85 | 0.305b
|
Histology | ||||
Endometrioid (%) | 181 (90.5 %) | 92 (92.0 %) | 89 (89.0 %) | 0.381c
|
Serous (%) | 13 (6.5 %) | 4 (4.0 %) | 9 (9.0 %) | |
Clear cell (%) | 4 (2.0 %) | 3 (3.0 %) | 1 (1.0 %) | |
Mucinous (%) | 2 (1.0 %) | 1 (1.0 %) | 1 (1.0 %) | |
Histological grade | ||||
Grade 1 | 86 (43.0 %) | 48 (48.0 %) | 38 (38.0 %) | 0.069b
|
Grade 2 | 85 (42.5 %) | 43 (43.0 %) | 42 (42.0 %) | |
Grade 3 | 29 (14.5 %) | 9 (9.0 %) | 20 (20.0 %) | |
Deep myometrial invasion (≥50 %) (%) | 46 (23.0 %) | 18 (18.0 %) | 28 (28.0 %) | 0.093b
|
Average tumor size (range), cm | 3.14 (0.2–20) | 3.19 (0.3–12) | 3.09 (0.2–20) | 0.791a
|
n = 165d
|
n = 84d
|
n = 81d
| ||
LN metastasis | 22 (11.0 %) | 6 (6.0 %) | 16 (16.0 %) |
0.024
b
|
Median No. retrieved LNs (range) | 25 (4–56) | 26 (4–55) | 24 (4–56) | 0.160a
|
Lympho-vascular invasion (%) | 37 (19.9 %) n = 186 | 17 (18.3 %) n = 93 | 20 (21.5 %) n = 93 | 0.582b
|
Extrauterine disease (%) | 28 (14.0 %) | 9 (9.0 %) | 19 (19.0 %) |
0.042
b
|
FIGO stage | ||||
IA (%) | 134 (67.0 %) | 73 (73.0 %) | 61 (61.0 %) | |
IB (%) | 23 (11.5 %) | 11 (11.0 %) | 12 (12.0 %) | |
II (%) | 15 (7.5 %) | 7 (7.0 %) | 8 (8.0 %) | |
IIIA (%) | 3 (1.5 %) | 2 (2.0 %) | 1 (1.0 %) | |
IIIB (%) | 2 (1.0 %) | 1 (1.0 %) | 1 (1.0 %) | |
IIIC (%) | 23 (11.5 %) | 6 (6.0 %) | 17 (17.0 %) | |
Median BMI (range), kg/m2
| 24.7 (17.5–43.7) | 24.6 (18.03–43.7) | 24.83 (17.53–35.16) | 0.280a
|
Median VAT (range), mm2
| 17338 (5990–37118) | 13780 (5990–31708) | 20187(6649–37188) |
<0.001
a
|
Median SAT (range), mm2
| 35607 (10458–106902) | 41395 (20347–106902) | 30360 (10458–61074) |
<0.001
a
|
Median VAT% (range) | 31.89 (13.97–59.57) | 25.99 (13.97–31.88) | 38.78(31.90–59.57) |
<0.001
a
|
Associations between obesity-related indices
BMI | Total | SAT | VAT | VAT% | ||
---|---|---|---|---|---|---|
BMI | Correlation coefficient | |||||
P value | ||||||
Total | Correlation coefficient | 0.667a
| ||||
P value | <0.001 | |||||
SAT | Correlation coefficient | 0.610a
| 0.913a
| |||
P value | <0.001 | <0.001 | ||||
VAT | Correlation coefficient | 0.428a
| 0.646a
| 0.279a
| ||
P value | <0.001 | <0.001 | <0.001 | |||
VAT% | Correlation coefficient | −0.049 | −0.123 | −0.504a
| 0.654a
| |
P value | 0.495 | 0.082 | <0.001 | <0.001 |
Association between VTA and parameters
Univariate | ||||
Parameters | Category | Cases | HR (95 % CI) |
P value |
Age | <54 | 102 | 1.58 (0.64–3.89) | 0.319 |
≥54 | 98 | |||
BMI | <24.7 | 101 | 1.02 (0.42–2.48) | 0.960 |
≥24.7 | 99 | |||
Cytology | Negative | 155 | 1.44 (0.30–6.99) | 0.652 |
Positive | 16 | |||
Grade | 1 + 2 | 171 | 5.47 (2.08–14.41) |
0.001
|
3 | 29 | |||
Tumor size | <2cm | 69 | 14.59 (1.92–111.14) |
0.010
|
≥2cm | 117 | |||
Histology | Endometrioid | 181 | 1.95 (0.90–4.20) | 0.090 |
Non-endometrioid | 19 | |||
Myometrial invasion depth | <50 % | 154 | 10.16 (3.82–26.99) |
<0.001
|
≥50 % | 46 | |||
LVSI | Negative | 149 | 86.47 (18.58–402.47) |
<0.001
|
Positive | 37 | |||
Extrauterine disease | No | 172 | Not applicablea
| 0.994 |
Yes | 28 | |||
VAT% | <31.89 | 100 | 2.98 (1.12–7.98) |
0.029
|
≥31.89 | 100 |
Multivariate | ||
Parameters | HR (95 % CI) |
P value |
Grade | 15.41 (1.60–148.76) |
0.018
|
Tumor size | 0.22 (0.04–1.42) | 0.112 |
Myometrial invasion depth | 1.40 (0.28–6.95) | 0.679 |
LVSI | 449.61 (31.27–6463.93) |
<0.001
|
VAT% | 6.37 (1.42–28.69) |
0.016
|